ENGLEWOOD, Colo., Feb. 4, 2026 /PRNewswire/ -- Zynex, Inc. (ZYXIQ), an innovative medical device company specializing in non-invasive medical devices for pain management, announced it has for the first time entered into a provider agreement with Humana Inc. (NYSE: HUM), effective February 1, 2026. About Zynex, Inc. Zynex, founded in 1996, is a pain management device manufacturer and distributor. For additional information, visit: www.zynex.com. Investor Relations Contact: Vikram Bajaj, CFO E-mail: [email pr ...

Core Viewpoint - Zynex, Inc. is addressing the federal indictments of two former executives while emphasizing its commitment to integrity and compliance under new leadership [1][2][3]. Company Response to Indictments - The individuals indicted are no longer with Zynex and do not influence current operations. Following the indictments, Thomas Sandgaard was removed as director and Chair of the Board [2]. - Zynex has not faced any criminal or civil charges [2]. Leadership and Compliance Overhaul - Over the past six months, Zynex has completely overhauled its leadership, compliance program, billing practices, and operational controls [3]. - The company is under new leadership and is committed to maintaining high integrity in its business practices with rigorous compliance oversight [3]. Cooperation with Authorities - Zynex has cooperated extensively with the Department of Justice and other regulators while seeking a long-term resolution to ongoing investigations [3]. Bankruptcy Proceedings - The company is currently reorganizing under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division [3]. Commitment to Future Operations - Zynex aims to build trust through transparency, integrity, and compliance while focusing on improving the quality of life for patients suffering from pain and other conditions [4].

Core Insights - The market has experienced significant declines in stock values of various companies, driven by market volatility, company-specific developments, and broader economic conditions [1][7] Company-Specific Summaries - Glenmede Women in Leadership US Eq (GWILX) saw its price drop by 48.32% to $8.79, indicating market skepticism about its performance despite its focus on gender diversity [2] - Harding Loevner Emerging Markets Portfolio Advisor Class (HLEMX) and Harding Loevner Institutional Emerging Markets Portfolio (HLMEX) experienced declines of 48.42% and 49.43%, respectively, reflecting the inherent risks of investing in volatile emerging markets [3] - SaverOne 2014 Ltd (SVRE) had a stock price decline of 46.61% to $1.89, with increased trading volume suggesting heightened investor interest or concern [4] - Zynex, Inc. (ZYXI) faced a dramatic decline of 55.33% to $0.29, entering Chapter 11 financial restructuring to stabilize its position amid challenges in the medical device sector [5] Market Trends - The significant price movements of these companies highlight the importance of understanding the factors driving market performance, including volatility, industry-specific challenges, and economic conditions [6][7]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 250 points, down 0.52% to 48,164.83, NASDAQ down 0.37% to 22,971.25, and S&P 500 down 0.56% to 6,778.08 [1] - European shares were lower, with the eurozone's STOXX 600 slipping 0.64%, Spain's IBEX 35 Index down 0.69%, London's FTSE 100 down 0.92%, Germany's DAX 40 down 0.85%, and France's CAC 40 declining 0.40% [5] - Asian markets closed lower, with Japan's Nikkei falling 1.56%, Hong Kong's Hang Seng down 1.54%, China's Shanghai Composite down 1.11%, and India's BSE Sensex down 0.63% [6] Economic Indicators - U.S. retail sales were flat for October compared to September, down from a revised 0.1% gain in the previous month and below market estimates of 0.1% growth [7] - The U.S. economy added 64,000 jobs in November, compared to a loss of 105,000 in the previous month and above market estimates of a 50,000 increase [9] - The U.S. unemployment rate rose to 4.6% in November from 4.3% in the previous month, marking the highest reading since September 2021 [9] - Average hourly earnings rose by 0.1% month-over-month to $36.86 in November, compared to a 0.4% rise in the previous month [9] - U.S. business inventories increased 0.2% month-over-month in September, in line with market estimates [9] - The S&P Global flash composite PMI declined to 53 in December, the lowest reading in six months, down from 54.2 in November [2][9] Commodity Market - In commodity news, oil traded down 2.9% to $55.17, while gold traded up 0.5% at $4,357.00 [4] Company News - SRx Health Solutions Inc shares surged 92% to $0.59 after announcing an agreement to acquire EMJ Crypto Technologies [8] - Rezolve AI PLC shares rose 34% to $3.12 following preliminary December revenue results [8] - Cementos Pacasmayo SAA shares increased 48% to $10.25 after Holcim signed an agreement to purchase 50.01% of the company's owner [8] - Zynex Inc shares dropped 53% to $0.31 after entering Chapter 11 court-supervised financial restructuring [8] - Lightwave Logic Inc shares fell 19% to $3.05 after announcing the pricing of an 11.67 million share common stock offering [8] - Navan Inc shares decreased 17% to $12.21 after reporting third-quarter results [8]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 250 points, down 0.52% to 48,164.83, NASDAQ down 0.37% to 22,971.25, and S&P 500 down 0.56% to 6,778.08 [1] - European shares were lower, with the eurozone's STOXX 600 slipping 0.64%, Spain's IBEX 35 Index down 0.69%, London's FTSE 100 down 0.92%, Germany's DAX 40 down 0.85%, and France's CAC 40 declining 0.40% [5] - Asian markets closed lower, with Japan's Nikkei down 1.56%, Hong Kong's Hang Seng down 1.54%, China's Shanghai Composite down 1.11%, and India's BSE Sensex down 0.63% [6] Economic Indicators - U.S. retail sales were flat for October compared to September, down from a revised 0.1% gain in the previous month and below market estimates of 0.1% growth [7] - The U.S. economy added 64,000 jobs in November, compared to a loss of 105,000 in the previous month and above market estimates of a 50,000 increase [9] - The U.S. unemployment rate rose to 4.6% in November from 4.3% in the previous month, marking the highest reading since September 2021 [9] - Average hourly earnings for private nonfarm payrolls rose by 0.1% month-over-month to $36.86 in November, compared to a 0.4% rise in the previous month [9] - U.S. business inventories increased 0.2% month-over-month in September, in line with market estimates [9] - The S&P Global flash composite PMI declined to 53 in December, the lowest reading in six months, down from 54.2 in November [2][9] Commodity Market - Oil traded down 2.9% to $55.17, while gold traded up 0.5% at $4,357.00, silver up 0.1% to $63.59, and copper down 1% to $5.3560 [4] Company News - SRx Health Solutions Inc shares surged 92% to $0.59 after announcing an agreement to acquire EMJ Crypto Technologies [8] - Rezolve AI PLC shares rose 34% to $3.12 following preliminary December revenue results [8] - Cementos Pacasmayo SAA shares increased 48% to $10.25 after Holcim signed an agreement to purchase 50.01% of the company's owner [8] - Zynex Inc shares dropped 53% to $0.31 after entering Chapter 11 court-supervised financial restructuring [8] - Lightwave Logic Inc shares fell 19% to $3.05 after announcing the pricing of an 11.67M share common stock offering [8] - Navan Inc shares decreased 17% to $12.21 after reporting third-quarter results [8]

Core Insights - Heartbeam Inc's shares increased significantly by 43.3% to $0.86 in pre-market trading following the announcement of its regulatory strategy after the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software [1][2] Company Developments - Heartbeam is exploring multiple regulatory options, including an appeal process or a 510(k) resubmission to demonstrate that its device is equivalent to legally marketed products [1] Market Movements - Other notable pre-market stock movements include: - SMX PLC surged 73.1% to $30.12 after a previous jump of 194% [6] - Zenta Group Co Ltd gained 26.7% to $3.18 [6] - Waton Financial Ltd rose 21.1% to $3.74 [6] - Verrica Pharmaceuticals Inc increased by 9.7% to $7.36 after announcing a $50 million private placement [6] - Conversely, several companies experienced declines, such as: - FBS Global Ltd fell 24.3% to $0.51 [6] - Tilray Brands Inc declined 15% to $0.88 following a reverse stock split announcement [6] - Solo Brands Inc dipped 14.4% to $7.19 after reporting disappointing third-quarter results [6]

Company Highlights - Zynex, Inc. (NASDAQ:ZYXI) experienced a 98% increase in stock price, reaching $1.46 from a low of $0.695, with a trading volume exceeding 66 million shares, driven by strong Q3 results [1][6] - Pasithea Therapeutics Corp. (KTTA) saw a 69.4% rise in stock price to $0.826, peaking at $1.34 during the day, with a trading volume of approximately 124 million shares, following a $1 million grant from the ALS Association for ALS research [2][6] - Amber International Holding Ltd (Nasdaq: AMBR) reported a 59.49% jump in stock price to $2.52, with over 85 million shares traded, and announced a $50 million share repurchase program, reflecting strong business momentum [3][6] - SMX (NASDAQ:SMX) saw its stock price climb by 58.21% to $9.35, with over 12 million shares traded, showcasing strong momentum at the 2025 DMCC Precious Metals Conference [4][6] Market Trends - The market is characterized by significant investor interest and stock price volatility across various sectors, including healthcare, biotechnology, real estate, and technology, driven by company-specific developments and broader market trends [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Zynex has released its financial results for the third quarter ending September 30, 2025, and is set to discuss projections and forward-looking statements during the earnings conference call [2][4]. Financial Results - The financial results for the third quarter of 2025 were made available on the company's website [2]. Future Projections - The company will provide forward-looking statements regarding future events, which may include product development, regulatory environment, and sales strategies [3][4].

Financial Data and Key Metrics Changes - Net revenue for Q3 2025 was $13.4 million, a significant decline from $50 million in Q3 2024, primarily due to TRICARE payment suspension and a $2.8 million reduction in revenue related to payments received during the suspension period [11][12] - Gross profit in Q3 2025 was $8.1 million, or 60% of revenue, compared to $39.8 million, or 80% of revenue, in Q3 2024 [12] - Net loss for Q3 2025 was $42.9 million, or $1.42 per share, compared to net income of $2.4 million in Q3 2024 [14] - Adjusted EBITDA loss for Q3 2025 was $12.3 million, compared to adjusted EBITDA of positive $5.1 million in Q3 2024 [14] - Cash and cash equivalents as of September 30, 2025, were $13.3 million, with a negative cash flow of $6.3 million for the quarter [7][14] Business Line Data and Key Metrics Changes - Device revenue for Q3 2025 was $7.1 million, while supplies revenue was $6.3 million, contributing to the overall decline in net revenue [11] - Workforce reductions in Q1 and Q2 2025 negatively impacted device orders and new patient onboarding, contributing to the revenue decline [12] Market Data and Key Metrics Changes - Changes to certain payers' claim submission and review practices have resulted in denials and payment delays, negatively impacting revenue [11] Company Strategy and Development Direction - The company is focused on a three-part strategy: addressing government agency concerns, managing near-term debt obligations, and improving revenue and cash flow performance [5][6][9] - A new resupply order fulfillment policy was implemented to enhance patient engagement and compliance [6][7] - The company is actively seeking to raise new capital to fund operations and address the maturity of $60 million in convertible senior notes due in May 2026 [6][8][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges ongoing challenges but expresses optimism about progress in implementing the turnaround strategy [10] - The company is engaging with government agencies in a collaborative manner to ensure compliance and integrity moving forward [6] Other Important Information - A non-cash asset impairment charge of $30.7 million was recorded in Q3 2025, primarily related to goodwill and certain fixed assets [14] - The company has entered a 30-day grace period regarding a $1.5 million interest payment due on convertible notes [15] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating that the call concluded without a Q&A segment [17]